Nomura Holdings
CLDI icon

Nomura Holdings’s Calidi Biotherapeutics CLDI Stock Holding History

Nomura Holdings’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,797
Closed -$9.3M – 1722
2022
Q2 		$9.3M Buy
7,797
+6,250
+404% +$7.44M 0.03% 361
2022
Q1 		$1.83M Buy
+1,547
New +$1.83M 0.01% 915

Other funds holding CLDI

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Nomura Holdings's CLDI Position: Q3 2022 in Review

Nomura Holdings sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 7,797 shares — an estimated $9.3M sold.

Nomura Holdings first reported a position in CLDI in Q1 2022 and held it in 2 quarters. The position peaked at $9.3M in Q2 2022. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

  • Nomura Holdings reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Nomura Holdings sold 7,797 Calidi Biotherapeutics shares in Q3 2022, an estimated $9.3M.
  • Nomura Holdings first reported a position in Calidi Biotherapeutics in Q1 2022 and held it in 2 quarters.
  • Nomura Holdings's Calidi Biotherapeutics position peaked at $9.3M in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on Nomura Holdings's 13F filing for Q3 2022, filed 15 Nov 2022.